# Sana Biotechnology (SANA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SANA
## Company Profile
- Ticker: SANA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Gene Therapy
## Stock Data
- Close: 3.77 USD
- Market cap: 901664751.6 USD
- Last updated: 2026-08-12
## Business Overview
### Engineered Cell Therapies
Sana Biotechnology develops engineered cells intended to repair or replace damaged biology while overcoming immune rejection. Its platform spans ex vivo cell replacement and in vivo delivery technologies.
### SC451 Islet-Cell Therapy
SC451 is a gene-modified, stem-cell-derived pancreatic islet-cell candidate designed to restore insulin production in people with type 1 diabetes without chronic immunosuppression. Sana is advancing the program in collaboration with Mayo Clinic.
### UP421 Clinical Validation
UP421 is a hypoimmune-modified primary islet-cell therapy being evaluated in an investigator-sponsored study without immunosuppression. Survival and insulin-producing function observed after transplantation provide human validation for the immune-evasion technology used in SC451.
### SG293 In Vivo CAR-T
SG293 uses a CD8-targeted fusosome to deliver genetic material that creates CD19-directed CAR-T cells inside the body. Sana plans to begin in non-Hodgkin lymphoma before potentially expanding into B-cell-mediated autoimmune diseases.
### SG227 Multiple-Myeloma Program
SG227 applies the same in vivo delivery approach to a BCMA-directed CAR for multiple myeloma. Its clinical entry is contingent on the initial safety and efficacy profile of SG293.
## Why The Stock Is Moving

As of Aug 12, 2026, SANA closed down 0.53% at $3.77. No new same-company headline was identified in the current news window.

## Future Catalysts

- IND submission and Phase 1/2 initiation for SC451 as early as 2026.
- First-in-human data for SG293 in non-Hodgkin lymphoma as early as 2026.
- Additional UP421 investigator-sponsored-study data at the EASD Annual Meeting on October 2, 2026.
- Clinical-study initiation for SG227 as early as mid-2027, contingent on the early SG293 clinical profile.

## Recent News
- 2026-08-10 20:05 EST — [Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/SANA/sana-biotechnology-reports-second-quarter-2026-financial-results-and-business-up-e1b7211a) — Source: Sana Biotechnology
- 2026-07-13 12:00 EST — [Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes](https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-follow-on-publication-in-the-new-england-journal-of-c0fc934b) — Source: Sana Biotechnology
- 2026-07-01 13:00 EST — [Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026](https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-symposium-presentation-at-the-european-association--26e086a1) — Source: Sana Biotechnology
- 2026-05-27 20:05 EST — [Sana Biotechnology to Present at June 2026 Investor Conferences](https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-june-2026-investor-conferences) — Source: Sana Biotechnology
- 2026-05-15 13:00 EST — [Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility](https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-sale-of-approximately-69-million-of-shares-through-its-at-the-market-atm-facility) — Source: Sana Biotechnology